技術面與產品面結合：剖析人壽當前市況下的窩輪選項

Core Viewpoint - China Life Insurance (02628) shows signs of stabilization in its stock price, currently at HKD 26.68, with a rise of 1.37% [1] Technical Analysis - The stock price has successfully risen above the 60-day moving average (HKD 24.32) and is close to the 10-day (HKD 26.68) and 30-day (HKD 26.15) moving averages, indicating a shift from weakness to stability in the short to medium term [1] - Momentum oscillators have issued a clear "buy" signal, corroborating the stock's stabilization above key moving averages [1] - However, the Ichimoku indicator has given a "sell" signal, suggesting a divergence in market sentiment regarding future momentum [1] Resistance and Support Levels - Key resistance is identified at HKD 27.3; if surpassed, the next target is HKD 28.1 [3] - Support levels are at HKD 25.4 (first line of defense) and HKD 24.9 (strong support area) [3] Derivative Market Insights - Historical performance of derivative tools shows significant leverage; for instance, on December 2, when China Life's stock fell by 3.00%, related bearish tools saw impressive returns, with Societe Generale's bear certificates (53450) and UBS's bear certificates (53368) rising by 23% within two days [3] - This highlights how derivatives can amplify returns during clear directional movements in the underlying stock [3] Investment Options - For bullish investors, two types of call options are recommended: Morgan Stanley's call option (19256) offers low premiums and favorable implied volatility, while UBS's call option (18990) provides another low-premium choice [6] - For bearish strategies, options like Bank of China's put option (19617) and UBS's put option (19408) offer relatively low premiums, while Societe Generale's bear certificate (53181) features a low premium and over 10x leverage [8]